AHA urged the House Energy and Commerce Committee to consider including in its draft legislation to address drug shortages legislative proposals that would support drug manufacturers and protect the supply chain for essential medications without limiting patient access to 340B drugs. 
 
“The AHA shares the committee’s concern about ensuring an adequate drug supply. Our member hospitals and health systems rely on drug therapies to care for their patients,” the association wrote. “In many cases, access to these critical drugs is in peril, jeopardizing patient health. Hospitals and health systems are most concerned about preserving consistent supply of and access to source generics and other generics, which drug manufacturers may believe lack sufficient business incentive to maintain. While the AHA believes shoring up the drug supply chain is of great importance, accomplishing this goal should not come at the cost of patient care. Reducing access to the 340B Drug Pricing Program would directly impact hospitals’ ability to offer a wide range of health care services to some of the nation’s most vulnerable populations.” 

Related News Articles

Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate…
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law…
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B…
Headline
The AHA May 8 filed an amicus brief in the U.S. District Court for the District of Nebraska in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
The AHA May 1 expressed concerns to the Centers for Medicare & Medicaid Services about the payment process established under the Medicare Drug…
Headline
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a report detailing findings from an investigation…